AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the ...
The first AI agent ran a ransomware attack end to end, signaling a shift to machine-speed cyberattacks and autonomous defense ...
Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...
Discover how Procter & Gamble applies its cleaning expertise to develop advanced recycling technologies like LAZRmark, ...
Contribute to EsmailLeath/Alemdar development by creating an account on GitHub.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results